Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9040-x
Annals of Surgical Oncology 14:230-238 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayes, A. J.
Right arrow Articles by Thomas, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, A. J.
Right arrow Articles by Thomas, J. M.

Original Article

Isolated Limb Perfusion With Melphalan and Tumor Necrosis Factor {alpha} for Advanced Melanoma and Soft-Tissue Sarcoma

Andrew J. Hayes, MD, PhD, Susan J. Neuhaus, MD, PhD, Matthew A. Clark, MD and J. Meirion Thomas, MD

Department of Surgery, Sarcoma and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, United Kingdom

Correspondence: Address correspondence and reprint requests to: Andrew J. Hayes, MD, PhD; E-mail: andrew.hayes{at}rmh.nhs.uk.

Background: Isolated limb perfusion (ILP) with melphalan is used in the treatment of advanced in-transit melanoma but has no real efficacy for irresectable soft tissue sarcomas arising in the extremities. The addition of tumor necrosis factor (TNF)-{alpha} may increase response rates for bulky melanoma and for sarcoma, but the potential for major systemic toxicity has limited its use.

Methods: Between October 2000 and April 2004, 49 ILPs were performed with melphalan and TNF-{alpha} . All procedures were performed with continuous leakage monitoring and regional hyperthermia.

Results: Forty-nine ILPs were performed for melanoma (n = 30), sarcoma (n = 16), or other tumors (n = 3). The most common indications were widespread in-transit disease for melanoma (n = 29) and irresectable primary disease for sarcoma (n = 9). Complete and partial responses for melanoma were 40% and 37%, and for sarcoma they were 20% and 33%. At a median follow-up of 14 months, 66% of melanoma patients who responded had not experienced local progression, compared with only 37% of sarcoma patients. Progression-free survival was significantly less for patients with sarcoma than melanoma (P = .0476). Four of 16 patients with sarcoma subsequently required amputation for progressive disease.

Conclusions: ILP with melphalan and TNF-{alpha} is a valuable treatment for advanced in-transit melanoma. Significant response rates were also seen in irresectable sarcoma, although the duration of response was limited.

Key Words: Isolated limb perfusion • Sarcoma • Melanoma • Tumor necrosis factor {alpha}






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.